256 related articles for article (PubMed ID: 32358087)
1. NEMESIS: Noninferiority, Individual-Patient Metaanalysis of Selective Internal Radiation Therapy with
Venerito M; Pech M; Canbay A; Donghia R; Guerra V; Chatellier G; Pereira H; Gandhi M; Malfertheiner P; Chow PKH; Vilgrain V; Ricke J; Leandro G
J Nucl Med; 2020 Dec; 61(12):1736-1742. PubMed ID: 32358087
[TBL] [Abstract][Full Text] [Related]
2. Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma.
Ricke J; Klümpen HJ; Amthauer H; Bargellini I; Bartenstein P; de Toni EN; Gasbarrini A; Pech M; Peck-Radosavljevic M; Popovič P; Rosmorduc O; Schott E; Seidensticker M; Verslype C; Sangro B; Malfertheiner P
J Hepatol; 2019 Dec; 71(6):1164-1174. PubMed ID: 31421157
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.
Vilgrain V; Pereira H; Assenat E; Guiu B; Ilonca AD; Pageaux GP; Sibert A; Bouattour M; Lebtahi R; Allaham W; Barraud H; Laurent V; Mathias E; Bronowicki JP; Tasu JP; Perdrisot R; Silvain C; Gerolami R; Mundler O; Seitz JF; Vidal V; Aubé C; Oberti F; Couturier O; Brenot-Rossi I; Raoul JL; Sarran A; Costentin C; Itti E; Luciani A; Adam R; Lewin M; Samuel D; Ronot M; Dinut A; Castera L; Chatellier G;
Lancet Oncol; 2017 Dec; 18(12):1624-1636. PubMed ID: 29107679
[TBL] [Abstract][Full Text] [Related]
4. Treatment options for unresectable HCC with a focus on SIRT with Yttrium-90 resin microspheres.
Wang EA; Stein JP; Bellavia RJ; Broadwell SR
Int J Clin Pract; 2017 Nov; 71(11):. PubMed ID: 28758319
[TBL] [Abstract][Full Text] [Related]
5. Selective internal radiation therapy compared with sorafenib for hepatocellular carcinoma with portal vein thrombosis.
Edeline J; Crouzet L; Campillo-Gimenez B; Rolland Y; Pracht M; Guillygomarc'h A; Boudjema K; Lenoir L; Adhoute X; Rohou T; Boucher E; Clément B; Blanc JF; Garin E
Eur J Nucl Med Mol Imaging; 2016 Apr; 43(4):635-43. PubMed ID: 26455499
[TBL] [Abstract][Full Text] [Related]
6. Tumor burden and liver function in HCC patient selection for selective internal radiation therapy: SARAH post-hoc study.
Palmer DH; Hawkins NS; Vilgrain V; Pereira H; Chatellier G; Ross PJ
Future Oncol; 2020 Jan; 16(1):4315-4325. PubMed ID: 31797680
[No Abstract] [Full Text] [Related]
7. Cost-effectiveness of selective internal radiation therapy with Y-90 resin microspheres for intermediate- and advanced-stage hepatocellular carcinoma in Brazil.
Agirrezabal I; Pereira Grillo Junior LS; Nasser F; Brennan VK; Bugano D; Galastri FL; da-Silva ALFA; Shergill S; da Motta-Leal-Filho JM
J Med Econ; 2023; 26(1):731-741. PubMed ID: 37139828
[TBL] [Abstract][Full Text] [Related]
8. SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma.
Chow PKH; Gandhi M; Tan SB; Khin MW; Khasbazar A; Ong J; Choo SP; Cheow PC; Chotipanich C; Lim K; Lesmana LA; Manuaba TW; Yoong BK; Raj A; Law CS; Cua IHY; Lobo RR; Teh CSC; Kim YH; Jong YW; Han HS; Bae SH; Yoon HK; Lee RC; Hung CF; Peng CY; Liang PC; Bartlett A; Kok KYY; Thng CH; Low AS; Goh ASW; Tay KH; Lo RHG; Goh BKP; Ng DCE; Lekurwale G; Liew WM; Gebski V; Mak KSW; Soo KC;
J Clin Oncol; 2018 Jul; 36(19):1913-1921. PubMed ID: 29498924
[TBL] [Abstract][Full Text] [Related]
9. Radioembolisation with yttrium‒90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial.
Vilgrain V; Abdel-Rehim M; Sibert A; Ronot M; Lebtahi R; Castéra L; Chatellier G;
Trials; 2014 Dec; 15():474. PubMed ID: 25472660
[TBL] [Abstract][Full Text] [Related]
10. VESPRO: An Individual Patient Data Prospective Meta-Analysis of Selective Internal Radiation Therapy Versus Sorafenib for Advanced, Locally Advanced, or Recurrent Hepatocellular Carcinoma of the SARAH and SIRveNIB Trials.
Gebski V; Gibbs E; Gandhi M; Chatellier G; Dinut A; Pereira H; Chow PK; Vilgrain V
JMIR Res Protoc; 2017 Feb; 6(2):e17. PubMed ID: 28202430
[TBL] [Abstract][Full Text] [Related]
11. Selective internal radiation therapies for unresectable early-, intermediate- or advanced-stage hepatocellular carcinoma: systematic review, network meta-analysis and economic evaluation.
Walton M; Wade R; Claxton L; Sharif-Hurst S; Harden M; Patel J; Rowe I; Hodgson R; Eastwood A
Health Technol Assess; 2020 Sep; 24(48):1-264. PubMed ID: 33001024
[TBL] [Abstract][Full Text] [Related]
12. Cost-utility analysis of selective internal radiation therapy with Y-90 resin microspheres in hepatocellular carcinoma.
Muszbek N; Remak E; Evans R; Brennan VK; Colaone F; Shergill S; Mullan D; Ross PJ
Future Oncol; 2021 Mar; 17(9):1055-1068. PubMed ID: 33222542
[No Abstract] [Full Text] [Related]
13. Liver function after combined selective internal radiation therapy or sorafenib monotherapy in advanced hepatocellular carcinoma.
Ricke J; Schinner R; Seidensticker M; Gasbarrini A; van Delden OM; Amthauer H; Peynircioglu B; Bargellini I; Iezzi R; De Toni EN; Malfertheiner P; Pech M; Sangro B
J Hepatol; 2021 Dec; 75(6):1387-1396. PubMed ID: 34454995
[TBL] [Abstract][Full Text] [Related]
14. Cost-Effectiveness Analysis of Selective Internal Radiotherapy With Yttrium-90 Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma.
Marqueen KE; Kim E; Ang C; Mazumdar M; Buckstein M; Ferket BS
JCO Oncol Pract; 2021 Feb; 17(2):e266-e277. PubMed ID: 33417490
[TBL] [Abstract][Full Text] [Related]
15. Safety and toxicity of radioembolization plus Sorafenib in advanced hepatocellular carcinoma: analysis of the European multicentre trial SORAMIC.
Ricke J; Bulla K; Kolligs F; Peck-Radosavljevic M; Reimer P; Sangro B; Schott E; Schütte K; Verslype C; Walecki J; Malfertheiner P;
Liver Int; 2015 Feb; 35(2):620-6. PubMed ID: 24930619
[TBL] [Abstract][Full Text] [Related]
16. A cost analysis of SIR-Spheres yttrium-90 resin microspheres versus tyrosine kinase inhibitors in the treatment of unresectable hepatocellular carcinoma in France, Italy, Spain and the UK.
Pollock RF; Colaone F; Guardiola L; Shergill S; Brennan VK
J Med Econ; 2020 Jun; 23(6):593-602. PubMed ID: 32067534
[No Abstract] [Full Text] [Related]
17. Comparison of the efficacy and safety of selective internal radiotherapy and sorafenib alone or combined for hepatocellular carcinoma: a systematic review and Bayesian network meta-analysis.
Zeng H; Zhou C; Chen X; Hu L; Su K; Guo L; Han Y
Clin Exp Med; 2023 Oct; 23(6):2141-2150. PubMed ID: 36737488
[TBL] [Abstract][Full Text] [Related]
18. Single administration of Selective Internal Radiation Therapy versus continuous treatment with sorafeNIB in locally advanced hepatocellular carcinoma (SIRveNIB): study protocol for a phase iii randomized controlled trial.
Gandhi M; Choo SP; Thng CH; Tan SB; Low AS; Cheow PC; Goh AS; Tay KH; Lo RH; Goh BK; Wong JS; Ng DC; Soo KC; Liew WM; Chow PK;
BMC Cancer; 2016 Nov; 16(1):856. PubMed ID: 27821083
[TBL] [Abstract][Full Text] [Related]
19. Relationship of Tumor Radiation-absorbed Dose to Survival and Response in Hepatocellular Carcinoma Treated with Transarterial Radioembolization with
Hermann AL; Dieudonné A; Ronot M; Sanchez M; Pereira H; Chatellier G; Garin E; Castera L; Lebtahi R; Vilgrain V;
Radiology; 2020 Sep; 296(3):673-684. PubMed ID: 32602828
[TBL] [Abstract][Full Text] [Related]
20. Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma.
Abdel-Rahman OM; Elsayed Z
Cochrane Database Syst Rev; 2016 Feb; 2():CD011313. PubMed ID: 26905230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]